← Leaderboards
Allison M Bradbury
Research Inst Nationwide Children'S Hosp
$1,820,728
Attributed
$2,626,373
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $993.5K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,626,373 · 5
By mechanism
R01$1,186,635 · 1
R00$686,113 · 1
R21$424,655 · 1
K99$178,352 · 1
F32$150,618 · 1
Top collaborators
- Mark Hester2 shared
- Josh Leitch Bonkowsky1 shared
Most similar at Research Inst Nationwide Children'S Hosp
Same institution · by research overlap
- Bruce A Bunnell$8,257,071
- Mark Hester$593,318
- Carlos E. Alvarez$396,000
- Jessica Audreyanna Herstine$77,282
Others in their field
Top investigators on “Biochemical”
- Michael W Weiner · Northern California Institute Res &Educ$74,211,055
- Bruce W Stillman · Cold Spring Harbor Laboratory$47,787,987
- John Damon Chodera · Sloan-Kettering Inst Can Research$47,159,667
- Nanduri R Prabhakar · Case Western Reserve University$46,495,566
- Richard C Boucher · University Of North Carolina Chapel Hill$44,019,683
- Peter D Karp · Sri International$43,901,053
Research focus
BiochemicalGene TherapyCellsAffectCessation Of LifeDisease ProgressionBrainTreatment EfficacyOligodendrogliaGenesSpinal CordTissuesDependovirusMyelinMediatingGloboid Cell LeukodystrophyLeukodystrophyMutationAnimal ModelGalactosylceramidesBiodistributionCell TypeCanis FamiliarisBreeding
Grant awards (11)
Uncovering mechanisms and developing novel therapeutic strategies for TBCD-related developmental and epileptic encephalopathy$568,866
R01 · FY2025 · NS · contact PI
Role of Microglia in Vanishing White Matter Disease Leukodystrophy$424,655
R21 · FY2025 · HD
Uncovering mechanisms and developing novel therapeutic strategies for TBCD-related developmental and epileptic encephalopathy$617,769
R01 · FY2024 · NS · contact PI
Temporospatial psychosine accumulation and targeted adeno-associated virus (AAV) gene therapy in canine Krabbe disease$244,020
R00 · FY2022 · HD · contact PI
Temporospatial psychosine accumulation and targeted adeno-associated virus (AAV) gene therapy in canine Krabbe disease$193,093
R00 · FY2021 · HD · contact PI
Temporospatial psychosine accumulation and targeted adeno-associated virus (AAV) gene therapy in canine Krabbe disease$249,000
R00 · FY2020 · HD · contact PI
Temporospatial psychosine accumulation and targeted adeno-associated virus (AAV) gene therapy in canine Krabbe disease$89,176
K99 · FY2019 · HD · contact PI
Temporospatial psychosine accumulation and targeted adeno-associated virus (AAV) gene therapy in canine Krabbe disease$89,176
K99 · FY2018 · HD · contact PI
Lentiviral-mediated Hematopoietic Stem Cell Gene Therapy for Canine Globoid Cell Leukodystrophy$35,334
F32 · FY2018 · NS · contact PI
Lentiviral-mediated Hematopoietic Stem Cell Gene Therapy for Canine Globoid Cell Leukodystrophy$59,166
F32 · FY2017 · NS · contact PI
Lentiviral-mediated Hematopoietic Stem Cell Gene Therapy for Canine Globoid Cell Leukodystrophy$56,118
F32 · FY2016 · NS · contact PI